Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 27;389(10084):2128-2137.
doi: 10.1016/S0140-6736(17)30063-6. Epub 2017 Mar 20.

Mortality Risk Disparities in Children Receiving Chronic Renal Replacement Therapy for the Treatment of End-Stage Renal Disease Across Europe: An ESPN-ERA/EDTA Registry Analysis


Mortality Risk Disparities in Children Receiving Chronic Renal Replacement Therapy for the Treatment of End-Stage Renal Disease Across Europe: An ESPN-ERA/EDTA Registry Analysis

Nicholas C Chesnaye et al. Lancet. .


Background: We explored the variation in country mortality rates in the paediatric population receiving renal replacement therapy across Europe, and estimated how much of this variation could be explained by patient-level and country-level factors.

Methods: In this registry analysis, we extracted patient data from the European Society for Paediatric Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry for 32 European countries. We included incident patients younger than 19 years receiving renal replacement therapy. Adjusted hazard ratios (aHR) and the explained variation were modelled for patient-level and country-level factors with multilevel Cox regression. The primary outcome studied was all-cause mortality while on renal replacement therapy.

Findings: Between Jan 1, 2000, and Dec 31, 2013, the overall 5 year renal replacement therapy mortality rate was 15·8 deaths per 1000 patient-years (IQR 6·4-16·4). France had a mortality rate (9·2) of more than 3 SDs better, and Russia (35·2), Poland (39·9), Romania (47·4), and Bulgaria (68·6) had mortality rates more than 3 SDs worse than the European average. Public health expenditure was inversely associated with mortality risk (per SD increase, aHR 0·69, 95% CI 0·52-0·91) and explained 67% of the variation in renal replacement therapy mortality rates between countries. Child mortality rates showed a significant association with renal replacement therapy mortality, albeit mediated by macroeconomics (eg, neonatal mortality reduced from 1·31 [95% CI 1·13-1·53], p=0·0005, to 1·21 [0·97-1·51], p=0·10). After accounting for country distributions of patient age, the variation in renal replacement therapy mortality rates between countries increased by 21%.

Interpretation: Substantial international variation exists in paediatric renal replacement therapy mortality rates across Europe, most of which was explained by disparities in public health expenditure, which seems to limit the availability and quality of paediatric renal care. Differences between countries in their ability to accept and treat the youngest patients, who are the most complex and costly to treat, form an important source of disparity within this population. Our findings can be used by policy makers and health-care providers to explore potential strategies to help reduce these health disparities.

Funding: ERA-EDTA and ESPN.

Comment in

Similar articles

See all similar articles

Cited by 6 articles

  • The copy number variation landscape of congenital anomalies of the kidney and urinary tract.
    Verbitsky M, Westland R, Perez A, Kiryluk K, Liu Q, Krithivasan P, Mitrotti A, Fasel DA, Batourina E, Sampson MG, Bodria M, Werth M, Kao C, Martino J, Capone VP, Vivante A, Shril S, Kil BH, Marasà M, Zhang JY, Na YJ, Lim TY, Ahram D, Weng PL, Heinzen EL, Carrea A, Piaggio G, Gesualdo L, Manca V, Masnata G, Gigante M, Cusi D, Izzi C, Scolari F, van Wijk JAE, Saraga M, Santoro D, Conti G, Zamboli P, White H, Drozdz D, Zachwieja K, Miklaszewska M, Tkaczyk M, Tomczyk D, Krakowska A, Sikora P, Jarmoliński T, Borszewska-Kornacka MK, Pawluch R, Szczepanska M, Adamczyk P, Mizerska-Wasiak M, Krzemien G, Szmigielska A, Zaniew M, Dobson MG, Darlow JM, Puri P, Barton DE, Furth SL, Warady BA, Gucev Z, Lozanovski VJ, Tasic V, Pisani I, Allegri L, Rodas LM, Campistol JM, Jeanpierre C, Alam S, Casale P, Wong CS, Lin F, Miranda DM, Oliveira EA, Simões-E-Silva AC, Barasch JM, Levy B, Wu N, Hildebrandt F, Ghiggeri GM, Latos-Bielenska A, Materna-Kiryluk A, Zhang F, Hakonarson H, Papaioannou VE, Mendelsohn CL, Gharavi AG, Sanna-Cherchi S. Verbitsky M, et al. Nat Genet. 2019 Jan;51(1):117-127. doi: 10.1038/s41588-018-0281-y. Epub 2018 Dec 21. Nat Genet. 2019. PMID: 30578417 Free PMC article.
  • Mortality Risks among Various Primary Renal Diseases in Children and Adolescents on Chronic Dialysis.
    Chou HH, Chiou YY, Chiou YH, Tain YL, Wang HH, Yu MC, Hsu CC, Lin CY. Chou HH, et al. J Clin Med. 2018 Nov 5;7(11):414. doi: 10.3390/jcm7110414. J Clin Med. 2018. PMID: 30400589 Free PMC article.
  • Genetic basis of human congenital anomalies of the kidney and urinary tract.
    Sanna-Cherchi S, Westland R, Ghiggeri GM, Gharavi AG. Sanna-Cherchi S, et al. J Clin Invest. 2018 Jan 2;128(1):4-15. doi: 10.1172/JCI95300. Epub 2018 Jan 2. J Clin Invest. 2018. PMID: 29293093 Free PMC article. Review.
  • Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.
    Lancia P, Aurich B, Ha P, Maisin A, Baudouin V, Jacqz-Aigrain E. Lancia P, et al. Clin Drug Investig. 2018 Feb;38(2):157-171. doi: 10.1007/s40261-017-0594-0. Clin Drug Investig. 2018. PMID: 29236209
  • Public health: Public investment in childhood health: worth the cost.
    Amaral S, Furth S. Amaral S, et al. Nat Rev Nephrol. 2017 Jul;13(7):386-388. doi: 10.1038/nrneph.2017.66. Epub 2017 May 30. Nat Rev Nephrol. 2017. PMID: 28555648 No abstract available.
See all "Cited by" articles